Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sunshine Biopharma (SBFMW) Restructuring Costs (2023 - 2025)

Historic Restructuring Costs for Sunshine Biopharma (SBFMW) over the last 5 years, with Q3 2025 value amounting to $614661.0.

  • Sunshine Biopharma's Restructuring Costs rose 1590.07% to $614661.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 million, marking a year-over-year increase of 1315.14%. This contributed to the annual value of $3.1 million for FY2024, which is 4516.86% up from last year.
  • Per Sunshine Biopharma's latest filing, its Restructuring Costs stood at $614661.0 for Q3 2025, which was up 1590.07% from $806605.0 recorded in Q2 2025.
  • In the past 5 years, Sunshine Biopharma's Restructuring Costs ranged from a high of $925878.0 in Q1 2025 and a low of $530334.0 during Q3 2024
  • In the last 3 years, Sunshine Biopharma's Restructuring Costs had a median value of $720297.0 in 2023 and averaged $741389.1.
  • Over the last 5 years, Sunshine Biopharma's Restructuring Costs had its largest YoY gain of 2578.92% in 2024, and its largest YoY loss of 255.06% in 2024.
  • Sunshine Biopharma's Restructuring Costs (Quarter) stood at $720297.0 in 2023, then rose by 25.79% to $906056.0 in 2024, then tumbled by 32.16% to $614661.0 in 2025.
  • Its Restructuring Costs was $614661.0 in Q3 2025, compared to $806605.0 in Q2 2025 and $925878.0 in Q1 2025.